Compare BioNano Genomics Inc (BNGO) vs Domino's Pizza, Inc. (DPZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Domino's Pizza, Inc. — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Domino's Pizza, Inc. trades at $352.37 (market cap $11.82B). The key difference: Domino's Pizza, Inc. is far larger — about 865.3× BioNano Genomics Inc's market cap, and Domino's Pizza, Inc. pays a 2.23% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | DPZ | |
|---|---|---|
Market Cap | $13.66M | $11.82B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $467.30 |
52-Week Low | $1.06 | $282.89 |
Enterprise Value | $16.26M | $16.78B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
DPZ trades at $353.57, up 1.64% today, with bullish technical signals from moving averages and a consensus analyst price target of $371.67. Recent earnings missed expectations in Q2 2026, but revenue grew to $4.94B in 2025 with a net income margin of 11.86%. The company launched a new individual-size pizza in August 2026 to boost sales, while high debt levels and weak premium pizza demand pose challenges.
The outlook is cautiously optimistic, supported by analyst buy ratings (53.85%) and innovation initiatives, but risks include rising input costs, competitive pressures, and insider selling. Investors should weigh strong cash flow generation against debt sustainability for long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →
